• Home
  • About Journal
    Journal Introduction
    Editorial Board
    Youth Editorial Board
    Cooperating Institutions
    Editorial Department
  • Submission Guidelines
  • Policies & Statements
    Ethical Guidelines for Publication
    Academic Misconduct Statement
    Open Access (OA) Statement
    AIGC Use Statement
  • Journal Subscription
  • Download Center
  • 中文版
Cite this article:
LI Weihua,DI Huifeng,CHEN Yingying,WANG Debao,LIU Peng.Effects of Mudan Particles combined with irbesartan on the levels of serum transforming growth factor-β1 and homocysteine in patients with early diabetic nephropathy[J].Journal Of Pharmaceutical Research,2016,35(9):545-547,558[Click to copy]
【Print this page】      【Download PDF Full Text】   【View/Add Comment】  【Download reader】  【 Close 】
←Previous|Next→ Archive    Advanced Search
This article has been viewed: 3602times   Download 3032次 QR Code for this article
Scan with your phone!
木丹颗粒联合厄贝沙坦对早期糖尿病肾病血浆转化生长因子β1和同型半胱氨酸的影响:一项随机、开放、平行、对照研究
李伟华,狄会峰,陈颖颖,王德宝,刘鹏
Font:Larger+|Default|Smaller-
(莱芜市人民医院,山东 莱芜 271100)
摘要:
目的 探讨木丹颗粒联合厄贝沙坦对2型糖尿病早期肾病患者血浆转化生长因子β1(TGF-β1)和同型半胱氨酸(Hcy)的影响。方法 采用前瞻性随机、开放、平行、对照的研究方法,将72例2型糖尿病早期肾病患者按随机数字表法分为厄贝沙坦组和木丹颗粒联合厄贝沙坦组(联合治疗组),观察2组基线及治疗48周后尿白蛋白排泄率(UAER)、尿β2微球蛋白(β2-MG)、血浆转化生长因子β1及同型半胱氨酸等水平的变化。结果 2组患者基线指标比较无统计学差异(P>0.05)。治疗48周后,2组治疗前后差值比较显示,联合治疗组较厄贝沙坦组能更好地降低尿白蛋白排泄率、尿β2微球蛋白和血浆血浆转化生长因子β1水平[(-37 12 对22 10) μg•min-1,(-0.40 0.17 对-0.24 0.12)mg•L-1,(-31 15 对-14 12)U•L-1,均P<0.01]。结论 与厄贝沙坦单药治疗相比,木丹颗粒联合厄贝沙坦能更好地降低血浆转化生长因子β1水平,减少尿白蛋白排泄和尿β2微球蛋白,可能具有一定的肾脏保护功能。
关键词:  木丹颗粒  糖尿病肾病  转化生长因子β1  同型半胱氨酸
DOI:10.13506/j.cnki.jpr.2016.09.015
基金项目:
Effects of Mudan Particles combined with irbesartan on the levels of serum transforming growth factor-β1 and homocysteine in patients with early diabetic nephropathy
LI Weihua,DI Huifeng,CHEN Yingying,WANG Debao,LIU Peng
(The People Hospital of Laiwu City, Laiwu 271100, China)
Abstract:
Objective To investigate the effects of Mudan Particles combined with irbesartan on the levels of serum transforming growth factor-β1 (TGF-β1) and homocysteine (Hcy) in patients with early diabetic nephropathy.Methods Application of prospectively randomized open parallel-controlled methods,a total of 72 patients with early diabetic nephropathy were selected, and were randomly divided into two groups for Mudan Particles combined with irbesartan (combined therapy) or irbesartan treatment, respectively.Changes in urinary albumin excretion rate (UAER),urine β2-microglobulin (β2-MG), the levels of serum TGF-β1 and Hcy were measured and compared between two groups at both pre- and post-treatment of 48 weeks.Results There were no statistically significant difference in the baseline clinical characteristics of study participants between two treatment groups (P>0.05 for all).Comparison of therapy-related differences between groups showed that the combined therapy was better in reducing UAER, urine β2-MG and serum TGF-β1 than the irbesartan group [(-37 12 vs 22 10) μg•min-1, (-0.40 0.17 vs -0.24 0.12)mg•L-1,(-31 15 vs-14 12)U•L-1,respectively,all P<0.01].Conclusion Compared with irbesartan monotherapy,Mudan Particles combined with irbesartan treatment can better reduce serum TGF-β1 levels,decrease UAER and urine β2-MG, and may exert kidney protection effects in patients with early diabetic nephropathy.
Key words:  Mudan Particles  Diabetic nephropathy  Transforming growth factor-β1  Homocysteine
Today's Visits:488    Total Visits:2383203
Website copyright:Editorial Board of Journal of Pharmaceutical Research     鲁ICP备17018036号-3     鲁公网安备 37010202001351号
Sponsored by:Shandong Institute for Food and Drug Control Shandong Pharmaceutical Association Address:No.2749 Xinluo Street,High-Tech Zone,Jinan,P.R.China Postcode:250101
Telephone Number:0531-81216586 Email :yaoxueyanjiu@163.com;yaoxueyanjiu@126.com
Technical Support:Beijing Qinyun Technology Co., Ltd.